Effect of steroid pulses in severe BK virus allograft nephropathy with extensive interstitial inflammation.
BK virus associated nephropathy
graft loss
steroid pulse
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
28 Mar 2024
28 Mar 2024
Historique:
revised:
09
02
2024
received:
21
08
2023
accepted:
12
02
2024
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
28
3
2024
Statut:
aheadofprint
Résumé
As there is no specific antiviral treatment currently available for BK polyomavirus associated nephropathy (BKVAN), its management relies on immunosuppression reduction in kidney transplant patients. Data on efficacy of steroid pulses in this indication are lacking. We performed a retrospective monocenter study on 64 patients diagnosed with biopsy-proven BKVAN. Patients within the "pulse group" (n = 37) received IV methylprednisolone 10 mg/kg 3 days consecutively. In the "low dose" steroid group (n = 27), patients were continued oral prednisone 5 mg daily. Mean follow up was 78 months in the steroid pulse group and 56 months in the low dose group (p = 0.15). Mean eGFR values at diagnosis were comparable, as well as other demographic characteristics. Mean BK plasma viral load was higher in "pulse" than in "low dose" steroid group. Pulse group had higher inflammation and tubulitis (p < 0.05). Graft loss reached 57% in the "pulse" group versus 41% in the "low dose" group, p = 0.20. Rejection events were similar. No major adverse event was statistically associated with steroid pulse, including infections, cancer, and de novo diabetes. No significant differences were found in the evolution of both groups of patients, despite patients receiving "pulse" steroids were identified as the most severe sharing higher BK viral load and more frequent active lesions on histology.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14260Informations de copyright
© 2024 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC.
Références
Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal‐transplant recipients. New England Journal of Medicine. 2002;347(7):488‐496. doi:10.1056/NEJMoa020439
Huang G, Wu L wei, Yang SC, et al. Factors influencing graft outcomes following diagnosis of polyomavirus ‐associated nephropathy after renal transplantation. In: Stepkowski S, ed. PLoS One. 2015;10(11):e0142460. doi:10.1371/journal.pone.0142460
Schwarz A, Linnenweber‐Held S, Heim A, et al. Factors influencing viral clearing and renal function during polyomavirus BK‐associated nephropathy after renal transplantation. Transplant J. 2012;94(4):396‐402. doi:10.1097/TP.0b013e31825a505d
Drachenberg CB, Papadimitriou JC, Chaudhry MR, et al. Histological evolution of BK virus‐associated nephropathy: importance of integrating clinical and pathological findings. Am J Transplant. 2017;17(8):2078‐2091. doi:10.1111/ajt.14314
Elfadawy N, Flechner SM, Schold JD, et al. Transient versus persistent BK viremia and long‐term outcomes after kidney and kidney–pancreas transplantation. Clin J Am Soc Nephrol. 2014;9(3):553‐561. doi:10.2215/CJN.08420813
Kim H, Yang WS, Han DJ, Park SK. Clinical courses of renal transplant recipients with high BK viremia. Transplant Proc. 2013;45(8):2975‐2979. doi:10.1016/j.transproceed.2013.08.033
Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis. 2003;3(10):611‐623.
Dalianis T, Eriksson BM, Felldin M, et al. Management of BK‐virus infection—Swedish recommendations. Infect Dis. 2019;51(7):479‐484. doi:10.1080/23744235.2019.1595130
Hirsch HH, Randhawa PS, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13528. doi:10.1111/ctr.13528
Ponticelli C, Locatelli F. Glucocorticoids in the treatment of glomerular diseases: pitfalls and pearls. Clin J Am Soc Nephrol. 2018;13(5):815‐822. doi:10.2215/CJN.12991117
Hirsch HH, Randhawa P. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):179‐188. doi:10.1111/ajt.12110
Kim H, Yu H, Baek CH, Han DJ, Park SK. High‐dose steroid therapy in BK viremia adversely affected the long‐term graft function after kidney transplantation. Transpl Infect Dis. 2016;18(6):844‐849. doi:10.1111/tid.12604
Dadhania D, Snopkowski C, Ding R, et al. Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication. Transplantation. 2008;86(4):521‐528. doi:10.1097/TP.0b013e31817c6447
Kayler LK, Batal I, Mohanka R, et al. Antirejection treatment in kidney transplant patients with BK viruria. Transplantation. 2008;86(6):797‐803. doi:10.1097/TP.0b013e3181837802
Sood P, Senanayake S, Sujeet K, et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single‐center study. Transplantation. 2012;94(8):814‐821. doi:10.1097/TP.0b013e31826690c6
Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell‐ and antibody‐mediated rejection. Am J Transplant. 2020;20(9):2318‐2331. doi:10.1111/ajt.15898
Mohamed M, Parajuli S, Muth B, et al. In kidney transplant recipients with BK polyomavirus infection, early BK nephropathy, microvascular inflammation, and serum creatinine are risk factors for graft loss. Transpl Infect Dis. 2016;18(3):361‐371. doi:10.1111/tid.12530
Park WY, Kang SS, Jin K, Park SB, Choe M, Han S. Long‐term prognosis of BK virus‐associated nephropathy in kidney transplant recipients. Kidney Res Clin Pract. 2018;37(2):167‐173. doi:10.23876/j.krcp.2018.37.2.167
Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, Cohen EP. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int. 2005;68(4):1834‐1839. doi:10.1111/j.1523‐1755.2005.00602.x
Gupta G, Kuppachi S, Kalil RS, Buck CB, Lynch CF, Engels EA. Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States. Am J Transplant. 2018;18(1):245‐252. doi:10.1111/ajt.14530
Masutani K, Shapiro R, Basu A, Tan H, Wijkstrom M, Randhawa P. The Banff 2009 Working Proposal for polyomavirus nephropathy: a critical evaluation of its utility as a determinant of clinical outcome. Am J Transplant. 2012;12(4):907‐918. doi:10.1111/j.1600‐6143.2012.03993.x
Nankivell BJ, P'Ng CH, Shingde M, et al. The pathophysiology and impact of inflammation in nonscarred renal interstitium. Transplantation. 2020;104:1. doi:10.1097/TP.0000000000002887
Moens U, Subramaniam N, Johansen B, Johansen T, Traavik T. A steroid hormone response unit in the late leader of the noncoding control region of the human polyomavirus BK confers enhanced host cell permissivity. J Virol. 1994;68(4):2398‐2408.
Bethge T, Hachemi HA, Manzetti J, Gosert R, Schaffner W, Hirsch HH. Sp1 sites in the noncoding control region of BK polyomavirus are key regulators of bidirectional viral early and late gene expression. In: Imperiale MJ, ed. J Virol. 2015;89(6):3396‐3411. doi:10.1128/JVI.03625‐14
Thölking G, Schmidt C, Koch R, et al. Influence of tacrolimus metabolism rate on BKV infection after kidney transplantation. Sci Rep. 2016;6(1):32273. doi:10.1038/srep32273
Gosert R, Rinaldo CH, Funk GA, et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med. 2008;205(4):841‐852. doi:10.1084/jem.20072097